Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon
Formato: article
Lenguaje:EN
Publicado: Korean Diabetes Association 2021
Materias:
diabetes mellitus, type 2
drug therapy, combination
glycated hemoglobin a
korea
metformin
vildagliptin
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Acceso en línea:https://doaj.org/article/cecc7af70b0d46858cf7813f8e5cd318
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/cecc7af70b0d46858cf7813f8e5cd318

Ejemplares similares